Navigation Links
Clarient Reports 2009 Third Quarter; Nine Month Results
Date:11/3/2009

ded September 30, 2009, loss from continuing operations before income taxes was $4.9 million compared to a loss from continuing operations before income taxes of $7.4 million for the nine months ended September 30, 2008.

Clarient's net loss for the third quarter 2009 was $3.2 million, or ($0.04) per share applicable to common stockholders. In the third quarter of 2008, the Company reported a net loss of $2.2 million, or ($0.03) per share applicable to common stockholders.

For the nine months ended September 30, 2009 and 2008, the net loss was $3.4 million and $7.4 million, respectively. Net loss per share applicable to common stockholders for the nine months ended September 30, 2009 and 2008 was ($0.10) and ($0.10), respectively.

Adjusted EBITDA (defined below) for the 2009 third quarter was a negative $1.6 million, compared to adjusted EBITDA of $1.4 million in the third quarter of 2008. For the 2009 nine-month period, adjusted EBITDA was $3.1 million, compared to adjusted EBITDA of $2.6 million in the prior year period, an increase of 19 percent.

Operating expenses were $14.7 million for the third quarter of 2009, compared to $10.2 million in the same quarter of 2008. For the first nine months of 2009, operating expenses totaled $40.5 million, compared to $29.0 million in the year-earlier period. The increase in operating expenses in the third quarter of 2009 versus the comparable period in 2008 was largely related to additional sales and marketing personnel costs and investment in our information technology infrastructure.

At September 30, 2009, Clarient's cash and cash equivalents totaled $8.1 million compared with $1.8 million at December 31, 2008.

Ray Land, Senior Vice President and Chief Financial Officer, said, "In the long term we will greatly benefit from the changes we made this quarter. The new information will allow us to better estimate our expected reimbursement rates, give us
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
2. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
3. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
4. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. Jim Agnello to Resign as Clarient Chief Financial Officer
8. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
9. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
10. Clarient to Commercialize Novel Breast Cancer Profile
11. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 ... the "Global Metabolomics Market 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 Metabolomics or Metabonomics is ... Metabolomics has become a new experimental technique that ... the environmental sciences. Metabolites are small molecules that ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 WABC Radio show ... Pet with Lorry Young will be hosting California-based Vet-Stem, ... about stem cell therapy in pets. Dr. Harman first ... of stem cell therapy for pets suffering from osteoarthritis and ... Regenerative Veterinary Medicine industry forward. , Young has invited Dr. ...
(Date:7/25/2014)... Lawrence Livermore scientists Charles Westbrook and William ... " The World's Most Influential Scientific Minds ." , ... who were identified by analyzing citation data over the ... highest-impact work (2002-2012 and 2012-2013). The two were selected ... . , "This recognition is a great honor for ...
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Xybion Corporation, ... for global corporations operating in highly regulated industries, ... first annual Global User Group Conference, Xybion International ... Philadelphia, Pennsylvania at the Sheraton ... http://photos.prnewswire.com/prnh/20140724/130263 This year,s conference ...
Breaking Biology Technology:Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3
... Pharmaceuticals, Inc. (NYSE Amex: ANX ) today ... ended December 31, 2008."2008 was a transition year for ... focused on lower-risk reformulations of previously-approved drugs. We achieved ... the difficult economic environment, we were unable to attract ...
... Insmed Inc. (Nasdaq: INSM ), a developer of ... March 23, 2009, NASDAQ issued a notice further extending the ... price and those rules requiring a minimum market value of ... effect through Friday, July 17, 2009, and the original rules ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... patient enrolment in its U.K. clinical trial to ... REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients ... neck. The principal investigators are Dr. Johann de ...
Cached Biology Technology:ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 2ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 3ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 4ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 5ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 6ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 7Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 3
(Date:7/25/2014)... WASHINGTON (July 24, 2014)The link between autism and ... the puzzle of the disease, and is largely ... Foundation Autism Research Initiative (SFARI), George Washington University ... to offer truly integrative and in-depth answers to ... research. , LaMantia, professor of pharmacology and ...
(Date:7/25/2014)... Prediabetes and Diabetes increasingly consume the healthcare ... immediate attention. , To address the ... impacting low-and middle-income countries, global leaders in ... research in diabetes prevention and development of ... important text. , This book on ...
(Date:7/25/2014)... After development of diffusion tensor tractography (DTT), which ... reconstruction and estimation for three motor tracts, such ... the corticoreticular pathway became possible. The corticospinal tract ... for motor function in the human brain. Several ... tract by transtentorial herniation. In addition, some studies ...
Breaking Biology News(10 mins):GW researcher receives grant to answer the how and why of autism during development 2What constitutes an effective response to the global 'diabesity' tsunami? 2
... and lizards likely gave birth to live young, rather than ... forth in their preferred reproductive mode, according to research published ... "This is a very unusual and controversial finding, and a ... Pyron, Robert F. Griggs Assistant Professor of Biology in the ...
... of millions of Americans, there,s no such thing as the ... hear a constant ringing, buzzing, hissing, humming or other noise ... be debilitating and life-altering. Now, University of Michigan ... what is going on inside their unquiet brains. The ...
... research indicates that for loggerhead sea turtles in the Northwest ... and favorable climate conditions in the year or two prior ... of nests produced by these animals in a given year. ... loggerheads, nesting increases since 2008 may be a recovery response ...
Cached Biology News:Ancestor of snakes, lizards likely gave birth to live young 2U-M tinnitus discovery opens door to possible new treatment avenues 2U-M tinnitus discovery opens door to possible new treatment avenues 3Loggerhead sea turtle nesting activity driven by recent climate conditions and returning nesting 2Loggerhead sea turtle nesting activity driven by recent climate conditions and returning nesting 3Loggerhead sea turtle nesting activity driven by recent climate conditions and returning nesting 4
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
...
PURA Immunogen: PURA (NP_005850, 183 a.a. ~ 293 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: